{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:05Z","timestamp":1790649725868,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.pupt.2021.102100","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:36:29Z","timestamp":1638272189000},"page":"102100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-7498","authenticated-orcid":false,"given":"Minshan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pupt.2021.102100_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019876545","article-title":"Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension","volume":"10","author":"Rothman","year":"2020","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.pupt.2021.102100_bib2","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/DDDT.S103534","article-title":"Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy","volume":"10","author":"Hardin","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.pupt.2021.102100_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019862167","article-title":"EXPRESS: transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients","volume":"9","author":"Holthaus","year":"2019","journal-title":"Pulm. Circ."},{"issue":"1","key":"10.1016\/j.pupt.2021.102100_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/17476348.2016.1121103","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"10","author":"Sharma","year":"2016","journal-title":"Expet Rev. Respir. Med."},{"issue":"14","key":"10.1016\/j.pupt.2021.102100_bib5","first-page":"135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","author":"Xiang Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.pupt.2021.102100_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019832199","article-title":"Real-life data on Selexipag for the treatment of pulmonary hypertension","volume":"9","author":"Barnikel","year":"2019","journal-title":"Pulm. Circ."},{"issue":"3","key":"10.1016\/j.pupt.2021.102100_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.1375","article-title":"Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study","volume":"21","author":"Beghetti","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.pupt.2021.102100_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00408-019-00222-7","article-title":"Real-life experience with selexipag as an add-on therapy to oral combination therapy in patients with pulmonary arterial or distal chronic thromboembolic pulmonary hypertension: a retrospective analysis","volume":"197","author":"Berlier","year":"2019","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.pupt.2021.102100_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.healun.2018.09.003","article-title":"McLaughlin.Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: results from the TRANSIT-1 study","volume":"38","author":"Frost","year":"2019","journal-title":"J. Heart Lung Transplant."},{"issue":"2","key":"10.1016\/j.pupt.2021.102100_bib10","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.pupt.2021.102100_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"26","key":"10.1016\/j.pupt.2021.102100_bib12","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.pupt.2021.102100_bib13","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1253\/circj.CJ-20-0438","article-title":"Selexipag for chronic thromboembolic pulmonary hypertension in Japanese patients- A double-blind, randomized, placebo-controlled, multicenter phase II study","volume":"84","author":"Tanabe","year":"2020","journal-title":"Circ. J."},{"issue":"9","key":"10.1016\/j.pupt.2021.102100_bib14","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1253\/circj.CJ-16-1348","article-title":"Efficacy and safety of an orally administered selective prostacyclin receptor agonist, selexipag, in Japanese patients with pulmonary arterial hypertension","volume":"81","author":"Tanabe","year":"2017","journal-title":"Circ. J."},{"issue":"4","key":"10.1016\/j.pupt.2021.102100_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/FJC.0000000000000800","article-title":"Experience in transitioning from parenteral prostacyclins to selexipag in pulmonary arterial hypertension","volume":"75","author":"Kishan","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.pupt.2021.102100_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"},{"issue":"Suppl 14","key":"10.1016\/j.pupt.2021.102100_bib17","doi-asserted-by":"crossref","first-page":"S1767","DOI":"10.21037\/jtd.2019.09.14","article-title":"Pharmacotherapy for pulmonary arterial hypertension","volume":"11","author":"Parikh","year":"2019","journal-title":"Thorac. Dis."},{"key":"10.1016\/j.pupt.2021.102100_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.pupt.2021.102100_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.pupt.2021.102100_bib20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2021.102100_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619843774","article-title":"Baseline history of patients using selexipag for pulmonary arterial hypertension","volume":"13","author":"Highland","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"7","key":"10.1016\/j.pupt.2021.102100_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/psp4.12202","article-title":"Population modeling of selexipag pharmacokinetics and clinical response parameters in patients with pulmonary arterial hypertension","volume":"6","author":"Krause","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"6","key":"10.1016\/j.pupt.2021.102100_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.pupt.2021.102100_bib24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-[4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino]butoxy]- N-(methylsulfonyl)acetam ide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"KuwanoK","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"10_S","key":"10.1016\/j.pupt.2021.102100_bib25","article-title":"Effect of selexipag on morbidity\/mortality in pulmonary arterial hypertension: results of the GRIPHON study","volume":"65","author":"McLaughlin","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.pupt.2021.102100_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020911831","article-title":"Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis","volume":"10","author":"McConnell","year":"2020","journal-title":"Pulm. Circ."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921001127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921001127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:33Z","timestamp":1761082233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553921001127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":26,"alternative-id":["S1094553921001127"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102100","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102100"}}